Marilena Gilca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marilena Gilca has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Irina Stoian
Department of Functional Sciences I/Biochemistry, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
18 shared publications - Adelina Vlad
Department of Functional Sciences I/Physiology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
7 shared publications - Dorin Dragos
Department of Medical Semiology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
7 shared publications Laura Gaman
Faculty of General Medicine
7 shared publicationsValeriu Atanasiu
5 shared publicationsV Atanasiu
Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
4 shared publications
Latest Publications
- Open Access
- 12 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2086
Plasma Zonulin as a Biomarker of Divergent Channels Latency in Systemic Lupus Erythematosus?
Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a chronic intermittent course, a characteristic that suggests an involvement of divergent channels. According to Chinese medicine, divergent channels divert the pathogens to joints, where they are held transiently in a latent state, in order to keep them away from internal organs. The purpose of the present work is to determine whether, in SLE subjects, the levels of certain markers of gut leakage (zonulin), fungal translocation or proliferation of [(1→3)-β-D-glucan], and protective mechanisms (FGF21) are associated with the type of organ involvement or with the type of joint involvement (small vs. large joints) and to explore potential connections with the Chinese medicine perspective on SLE, conceptualized as pathology of the divergent channels. Methods: The study had a cross-sectional design and included an SLE group (n = 33) and a control group (n = 24) of subjects. Plasma levels of zonulin, (1→3)-β-D-glucan, and FGF21 were measured using indirect ELISA. Results: Despite the fact that SLE patients exhibited higher plasma zonulin levels when compared to controls [4.709 (1.996–10.426), n = 33 vs. 1.973 (1.371–3.05925), n = 24, p = 0.004], [median (IQR)], there was no difference in plasma zonulin levels between SLE patients with large joint involvement and controls. Plasma (1→3)-β-D-glucan was also higher in the SLE group than in controls [119.444 (82.746–277.66), n = 33 vs. 77.893 (47.524–124.7495), n = 24, p = 0.01]. Cutaneous involvement was significantly more frequent in patients with large joint (p = 0.03) and small joint (p = 0.006) involvement than in those without articular involvement. Conclusions: Plasma zonulin may be correlated with the degree of SLE latency in joints (divergent channels activation). The engagement of divergent channels, reflected by articular involvement, appears to be associated with a greater propensity for sinew channel activation as a potential mechanism of pathogen evacuation.
- 12 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2086
Open AccessPlasma Zonulin as a Biomarker of Divergent Channels Latency in Systemic Lupus Erythematosus?
Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a chronic intermittent course, a characteristic that suggests an involvement of divergent channels. According to Chinese medicine, divergent channels divert the pathogens to joints, where they are held transiently in a latent state, in order to keep them away from internal organs. The purpose of the present work is to determine whether, in SLE subjects, the levels of certain markers of gut leakage (zonulin), fungal translocation or proliferation of [(1→3)-β-D-glucan], and protective mechanisms (FGF21) are associated with the type of organ involvement or with the type of joint involvement (small vs. large joints) and to explore potential connections with the Chinese medicine perspective on SLE, conceptualized as pathology of the divergent channels. Methods: The study had a cross-sectional design and included an SLE group (n = 33) and a control group (n = 24) of subjects. Plasma levels of zonulin, (1→3)-β-D-glucan, and FGF21 were measured using indirect ELISA. Results: Despite the fact that SLE patients exhibited higher plasma zonulin levels when compared to controls [4.709 (1.996–10.426), n = 33 vs. 1.973 (1.371–3.05925), n = 24, p = 0.004], [median (IQR)], there was no difference in plasma zonulin levels between SLE patients with large joint involvement and controls. Plasma (1→3)-β-D-glucan was also higher in the SLE group than in controls [119.444 (82.746–277.66), n = 33 vs. 77.893 (47.524–124.7495), n = 24, p = 0.01]. Cutaneous involvement was significantly more frequent in patients with large joint (p = 0.03) and small joint (p = 0.006) involvement than in those without articular involvement. Conclusions: Plasma zonulin may be correlated with the degree of SLE latency in joints (divergent channels activation). The engagement of divergent channels, reflected by articular involvement, appears to be associated with a greater propensity for sinew channel activation as a potential mechanism of pathogen evacuation.
- Open Access
- 18 January 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (1) , 97
Plant-Derived Agents and Systemic Sclerosis: A Systematic Review of Therapeutic Potential and Molecular Mechanisms
Systemic sclerosis (SSc) is a rare multisystemic autoimmune disease associated with progressive fibrosis, vasculopathy, and immune dysregulation. Despite advances in its management, the disease remains associated with substantial morbidity and mortality, with limited therapeutic options. This systematic review aimed to identify phytocompounds and medicinal plants that had demonstrated efficacy in SSc. A comprehensive literature search was performed in PubMed and ScienceDirect, yielding 7797 records, of which 32 studies met the inclusion criteria. A second search was performed using the SwissTargetPrediction tool to identify new putative molecular targets for these phytocompounds, whose relevance for SSc pathogenesis was verified by a third search in PubMed and ScienceDirect databases. Our search found 24 phytocompouds (e.g., halofunginone, crocetin, and tanshinone IIA) and 5 plant extracts (e.g., caper bush and ciplukan) reported to modulate key pathogenic processes in SSc. These phytochemicals were mainly associated with effects on endothelial to mesenchymal transition, oxidative stress, inflammation, and profibrotic signaling pathways, particularly TGF-β/Smad. The SwissTargetPrediction tool indicated 93 new potential molecular targets of the selected phytochemicals, among which only 41 showed relevance to SSc pathogenesis. In conclusion, available evidence is scarce but promising. Further studies, especially human investigations, are required to clarify clinical efficacy, safety, and potential interactions with drugs used in SSc.
- 18 January 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (1) , 97
Open AccessPlant-Derived Agents and Systemic Sclerosis: A Systematic Review of Therapeutic Potential and Molecular Mechanisms
Systemic sclerosis (SSc) is a rare multisystemic autoimmune disease associated with progressive fibrosis, vasculopathy, and immune dysregulation. Despite advances in its management, the disease remains associated with substantial morbidity and mortality, with limited therapeutic options. This systematic review aimed to identify phytocompounds and medicinal plants that had demonstrated efficacy in SSc. A comprehensive literature search was performed in PubMed and ScienceDirect, yielding 7797 records, of which 32 studies met the inclusion criteria. A second search was performed using the SwissTargetPrediction tool to identify new putative molecular targets for these phytocompounds, whose relevance for SSc pathogenesis was verified by a third search in PubMed and ScienceDirect databases. Our search found 24 phytocompouds (e.g., halofunginone, crocetin, and tanshinone IIA) and 5 plant extracts (e.g., caper bush and ciplukan) reported to modulate key pathogenic processes in SSc. These phytochemicals were mainly associated with effects on endothelial to mesenchymal transition, oxidative stress, inflammation, and profibrotic signaling pathways, particularly TGF-β/Smad. The SwissTargetPrediction tool indicated 93 new potential molecular targets of the selected phytochemicals, among which only 41 showed relevance to SSc pathogenesis. In conclusion, available evidence is scarce but promising. Further studies, especially human investigations, are required to clarify clinical efficacy, safety, and potential interactions with drugs used in SSc.
- Open Access
- 5 November 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 922
Increased Intestinal Permeability and Articular Involvement in Systemic Lupus Erythematosus Patients—A Mutually Exclusive Relationship?
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder characterized by complex interactions between the innate and adaptive immune systems, being potentially associated with an enhanced intestinal permeability. Zonulin represents a key protein in the modulation of intestinal permeability, being a gut leakage marker. The purpose of the present work was to evaluate the intestinal permeability, through serum zonulin levels, and to explore the relationships between zonulin, disease activity, and organ involvement in Caucasian SLE patients. The study had a cross-sectional design and included two groups of subjects: the SLE group (n = 41) and the control group (n = 29). Plasma zonulin level was measured using indirect ELISA. Despite the fact that Caucasian SLE patients exhibited higher plasma zonulin levels compared to the control group (7.566 ± 1.368 ng/mL vs. 2.306 ± 0.286 ng/mL, p < 0.01, Mann–Whitney-U-test), plasma zonulin levels did not correlate with disease activity measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). SLE patients with clinical articular involvement had paradoxically lower plasma zonulin levels than those without this manifestation. The results support the hypothesis of a mutually exclusive inflammatory “signature” between intestinal mucosa and synovium.
- 5 November 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 922
Open AccessIncreased Intestinal Permeability and Articular Involvement in Systemic Lupus Erythematosus Patients—A Mutually Exclusive Relationship?
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder characterized by complex interactions between the innate and adaptive immune systems, being potentially associated with an enhanced intestinal permeability. Zonulin represents a key protein in the modulation of intestinal permeability, being a gut leakage marker. The purpose of the present work was to evaluate the intestinal permeability, through serum zonulin levels, and to explore the relationships between zonulin, disease activity, and organ involvement in Caucasian SLE patients. The study had a cross-sectional design and included two groups of subjects: the SLE group (n = 41) and the control group (n = 29). Plasma zonulin level was measured using indirect ELISA. Despite the fact that Caucasian SLE patients exhibited higher plasma zonulin levels compared to the control group (7.566 ± 1.368 ng/mL vs. 2.306 ± 0.286 ng/mL, p < 0.01, Mann–Whitney-U-test), plasma zonulin levels did not correlate with disease activity measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). SLE patients with clinical articular involvement had paradoxically lower plasma zonulin levels than those without this manifestation. The results support the hypothesis of a mutually exclusive inflammatory “signature” between intestinal mucosa and synovium.
- Open Access
- 25 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7202
Modulation of Glutathione-S-Transferase by Phytochemicals: To Activate or Inhibit—That Is the Question
Glutathione S-transferases (GSTs) are phase II detoxification enzymes that display several enzymatic activities, including transferase, peroxidase, reductase, and isomerase functions, as well as non-enzymatic roles (e.g., serving as binding proteins). Their complex functionality lies in the biotransformation of xenobiotics (e.g., pesticides, drugs) and certain endogenous compounds, primarily metabolites produced by phase I detoxification enzymes. Several plant-derived compounds have been shown to modulate the activity and expression levels of these enzymes. Phytochemical activators of GSTs are potentially beneficial for detoxification in cases of exposure to various toxic compounds, whereas inhibitors of GSTs could have positive effects as adjuvant treatments for cancers that express high levels of GSTs associated with drug resistance.
- 25 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7202
Open AccessModulation of Glutathione-S-Transferase by Phytochemicals: To Activate or Inhibit—That Is the Question
Glutathione S-transferases (GSTs) are phase II detoxification enzymes that display several enzymatic activities, including transferase, peroxidase, reductase, and isomerase functions, as well as non-enzymatic roles (e.g., serving as binding proteins). Their complex functionality lies in the biotransformation of xenobiotics (e.g., pesticides, drugs) and certain endogenous compounds, primarily metabolites produced by phase I detoxification enzymes. Several plant-derived compounds have been shown to modulate the activity and expression levels of these enzymes. Phytochemical activators of GSTs are potentially beneficial for detoxification in cases of exposure to various toxic compounds, whereas inhibitors of GSTs could have positive effects as adjuvant treatments for cancers that express high levels of GSTs associated with drug resistance.
- Open Access
- 6 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1541890
Editorial: Women in ethnopharmacology: 2023
Despite the fact that the landscape of gender in education and the workforce regarding women 8 representation and recognition has improved lately, differences persist in various science-related fields 9 (Charlesworth and Banaji, 2019), women being more likely to experience non-standard professional 10 trajectories and negative health effects (Cabib et al., 2024). 11Realizing the importance of cultivating gender equality for sustainable development, as highlighted by 12 UNESCO, we initiated a Research Topic to provide a collaborative platform to promote the work of 13 women scientists, across all fields of Ethnopharmacology. In response to our call for submissions, 21 14 articles were submitted, of which only 11 met publication standards. 15In the following section of this editorial, some important achievements in the field will be highlighted, 16and also few topics for future research will be identified. 17One of the important health issues affecting 10% of the women of reproductive age is endometriosis 18 (Shafrir et al., 2018). Besides its negative impact on the quality of life, it also represents an economic 19 burden (Swift et al., 2024 ailments, but, surprisingly, also with the preference for harvesting rather than purchasing plants. The 57 authors also raised a concern regarding the necessity to protect this ethnomedical heritage, since there 58 is a significant reduction of used taxa when compared to the past. 59Although not statistically significant, women having a lower socio-economic status had a higher 60 cardiovascular risk than men (Ololade et al., 2024). Also women suffering of polycystic ovary 61 syndrome, a frequent endocrinopathy, have a higher chance to develop a cardiovascular disease (Dutta 62 and Maddukuri, 2024), while the leading cause of mortality in female breast cancer is represented by 63 the same type of cardiovascular pathology (Jiao et al., 2024). 64Given the importance of cardiovascular health on women wellbeing, in the present Research topic, 65 some space was granted to this area. The studies presented here highlights the diversity of research performed across the entire breadth of 75Ethnopharmacology and presents few advances in knowledge with applications to compelling women 76 related-health issues, such as endometriosis, cardiovascular and inflammatory diseases, while 77 identifying problems that requires attention, such as quality control of CHMs and preservation of 78 biocultural heritage. 79The editors expect the articles published in this Research Topic to have a significant impact on the 80 readers and believe that more women scientists will be thus encouraged to be involved in the 81 ethnopharmacological research, contributing to the development of new efficient therapeutic 82 approaches inspired by traditional medicine. 83
- 6 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1541890
Open AccessEditorial: Women in ethnopharmacology: 2023
Despite the fact that the landscape of gender in education and the workforce regarding women 8 representation and recognition has improved lately, differences persist in various science-related fields 9 (Charlesworth and Banaji, 2019), women being more likely to experience non-standard professional 10 trajectories and negative health effects (Cabib et al., 2024). 11Realizing the importance of cultivating gender equality for sustainable development, as highlighted by 12 UNESCO, we initiated a Research Topic to provide a collaborative platform to promote the work of 13 women scientists, across all fields of Ethnopharmacology. In response to our call for submissions, 21 14 articles were submitted, of which only 11 met publication standards. 15In the following section of this editorial, some important achievements in the field will be highlighted, 16and also few topics for future research will be identified. 17One of the important health issues affecting 10% of the women of reproductive age is endometriosis 18 (Shafrir et al., 2018). Besides its negative impact on the quality of life, it also represents an economic 19 burden (Swift et al., 2024 ailments, but, surprisingly, also with the preference for harvesting rather than purchasing plants. The 57 authors also raised a concern regarding the necessity to protect this ethnomedical heritage, since there 58 is a significant reduction of used taxa when compared to the past. 59Although not statistically significant, women having a lower socio-economic status had a higher 60 cardiovascular risk than men (Ololade et al., 2024). Also women suffering of polycystic ovary 61 syndrome, a frequent endocrinopathy, have a higher chance to develop a cardiovascular disease (Dutta 62 and Maddukuri, 2024), while the leading cause of mortality in female breast cancer is represented by 63 the same type of cardiovascular pathology (Jiao et al., 2024). 64Given the importance of cardiovascular health on women wellbeing, in the present Research topic, 65 some space was granted to this area. The studies presented here highlights the diversity of research performed across the entire breadth of 75Ethnopharmacology and presents few advances in knowledge with applications to compelling women 76 related-health issues, such as endometriosis, cardiovascular and inflammatory diseases, while 77 identifying problems that requires attention, such as quality control of CHMs and preservation of 78 biocultural heritage. 79The editors expect the articles published in this Research Topic to have a significant impact on the 80 readers and believe that more women scientists will be thus encouraged to be involved in the 81 ethnopharmacological research, contributing to the development of new efficient therapeutic 82 approaches inspired by traditional medicine. 83
- Open Access
L-Arginine-Dependent Nitric Oxide Production in the Blood of Patients with Type 2 Diabetes: A Pilot, Five-Year Prospective Study
Backgound: Type 2 diabetes mellitus (T2DM) is a major cardiovascular risk factor. Nitric oxide (NO) is one of the many molecules that regulate vascular tone, and red blood cells (RBCs) are known to play an important role in adjusting cardiac function through NO export from RBCs. Our study prospectively investigated the L-arginine (L-arg)–nitric oxide (NO) metabolic pathway in the erythrocytes and plasma of subjects with T2DM. Methods: RBCs and plasma were collected from patients with T2DM (n = 10), at first clinical onset (baseline) and after five years of disease evolution (follow-up). L-arg content was assayed by competitive enzyme-linked immunoassay. Arginase activity and nitrate/nitrite levels were measured using spectrophotometry. Results: When compared to baseline, L-arg content decreased in RBCs and remained similar in the plasma; NO production decreased in RBCs and the plasma; and arginase activity was lower in RBCs and increased in plasma. Conclusions: The L-arg/NO metabolic pathway decreases in the RBCs of patients with T2DM five years after the first clinical onset. The persistent decrease in RBCs’ arginase activity fails to compensate for the sustained decrease in RBCs’ NO production in the diabetic environment. This pilot study indicates that the NO-RBC pool is depleted during the progression of the disease in the same cohort of T2DM patients.
Open AccessL-Arginine-Dependent Nitric Oxide Production in the Blood of Patients with Type 2 Diabetes: A Pilot, Five-Year Prospective Study
Backgound: Type 2 diabetes mellitus (T2DM) is a major cardiovascular risk factor. Nitric oxide (NO) is one of the many molecules that regulate vascular tone, and red blood cells (RBCs) are known to play an important role in adjusting cardiac function through NO export from RBCs. Our study prospectively investigated the L-arginine (L-arg)–nitric oxide (NO) metabolic pathway in the erythrocytes and plasma of subjects with T2DM. Methods: RBCs and plasma were collected from patients with T2DM (n = 10), at first clinical onset (baseline) and after five years of disease evolution (follow-up). L-arg content was assayed by competitive enzyme-linked immunoassay. Arginase activity and nitrate/nitrite levels were measured using spectrophotometry. Results: When compared to baseline, L-arg content decreased in RBCs and remained similar in the plasma; NO production decreased in RBCs and the plasma; and arginase activity was lower in RBCs and increased in plasma. Conclusions: The L-arg/NO metabolic pathway decreases in the RBCs of patients with T2DM five years after the first clinical onset. The persistent decrease in RBCs’ arginase activity fails to compensate for the sustained decrease in RBCs’ NO production in the diabetic environment. This pilot study indicates that the NO-RBC pool is depleted during the progression of the disease in the same cohort of T2DM patients.
- Open Access
- 30 December 2023
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (1) , 299-326
Bitter Phytochemicals as Novel Candidates for Skin Disease Treatment
Skin diseases represent a global healthcare challenge due to their rising incidence and substantial socio-economic burden. While biological, immunological, and targeted therapies have brought a revolution in improving quality of life and survival rates for certain dermatological conditions, there remains a stringent demand for new remedies. Nature has long served as an inspiration for drug development. Recent studies have identified bitter taste receptors (TAS2Rs) in both skin cell lines and human skin. Additionally, bitter natural compounds have shown promising benefits in addressing skin aging, wound healing, inflammatory skin conditions, and even skin cancer. Thus, TAS2Rs may represent a promising target in all these processes. In this review, we summarize evidence supporting the presence of TAS2Rs in the skin and emphasize their potential as drug targets for addressing skin aging, wound healing, inflammatory skin conditions, and skin carcinogenesis. To our knowledge, this is a pioneering work in connecting information on TAS2Rs expression in skin and skin cells with the impact of bitter phytochemicals on various beneficial effects related to skin disorders.
- 30 December 2023
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (1) , 299-326
Open AccessBitter Phytochemicals as Novel Candidates for Skin Disease Treatment
Skin diseases represent a global healthcare challenge due to their rising incidence and substantial socio-economic burden. While biological, immunological, and targeted therapies have brought a revolution in improving quality of life and survival rates for certain dermatological conditions, there remains a stringent demand for new remedies. Nature has long served as an inspiration for drug development. Recent studies have identified bitter taste receptors (TAS2Rs) in both skin cell lines and human skin. Additionally, bitter natural compounds have shown promising benefits in addressing skin aging, wound healing, inflammatory skin conditions, and even skin cancer. Thus, TAS2Rs may represent a promising target in all these processes. In this review, we summarize evidence supporting the presence of TAS2Rs in the skin and emphasize their potential as drug targets for addressing skin aging, wound healing, inflammatory skin conditions, and skin carcinogenesis. To our knowledge, this is a pioneering work in connecting information on TAS2Rs expression in skin and skin cells with the impact of bitter phytochemicals on various beneficial effects related to skin disorders.
- Open Access
- 12 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16227
Relevance of Phytochemical Taste for Anti-Cancer Activity: A Statistical Inquiry
Targeting inflammation and the pathways linking inflammation with cancer is an innovative therapeutic strategy. Tastants are potential candidates for this approach, since taste receptors display various biological functions, including anti-inflammatory activity (AIA). The present study aims to explore the power different tastes have to predict a phytochemical’s anti-cancer properties. It also investigates whether anti-inflammatory phytocompounds also have anti-cancer effects, and whether there are tastes that can better predict a phytochemical’s bivalent biological activity. Data from the PlantMolecularTasteDB, containing a total of 1527 phytochemicals, were used. Out of these, only 624 phytocompounds met the inclusion criterion of having 40 hits in a PubMed search, using the name of the phytochemical as the keyword. Among them, 461 phytochemicals were found to possess anti-cancer activity (ACA). The AIA and ACA of phytochemicals were strongly correlated, irrespective of taste/orosensation or chemical class. Bitter taste was positively correlated with ACA, while sweet taste was negatively correlated. Among chemical classes, only flavonoids (which are most frequently bitter) had a positive association with both AIA and ACA, a finding confirming that taste has predictive primacy over chemical class. Therefore, bitter taste receptor agonists and sweet taste receptor antagonists may have a beneficial effect in slowing down the progression of inflammation to cancer.
- 12 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16227
Open AccessRelevance of Phytochemical Taste for Anti-Cancer Activity: A Statistical Inquiry
Targeting inflammation and the pathways linking inflammation with cancer is an innovative therapeutic strategy. Tastants are potential candidates for this approach, since taste receptors display various biological functions, including anti-inflammatory activity (AIA). The present study aims to explore the power different tastes have to predict a phytochemical’s anti-cancer properties. It also investigates whether anti-inflammatory phytocompounds also have anti-cancer effects, and whether there are tastes that can better predict a phytochemical’s bivalent biological activity. Data from the PlantMolecularTasteDB, containing a total of 1527 phytochemicals, were used. Out of these, only 624 phytocompounds met the inclusion criterion of having 40 hits in a PubMed search, using the name of the phytochemical as the keyword. Among them, 461 phytochemicals were found to possess anti-cancer activity (ACA). The AIA and ACA of phytochemicals were strongly correlated, irrespective of taste/orosensation or chemical class. Bitter taste was positively correlated with ACA, while sweet taste was negatively correlated. Among chemical classes, only flavonoids (which are most frequently bitter) had a positive association with both AIA and ACA, a finding confirming that taste has predictive primacy over chemical class. Therefore, bitter taste receptor agonists and sweet taste receptor antagonists may have a beneficial effect in slowing down the progression of inflammation to cancer.
- Open Access
Phytochemicals and Inflammation: Is Bitter Better?
The taste of a herb influences its use in traditional medicine. A molecular basis for the taste-based patterns ruling the distribution of herbal (ethno) pharmacological activities may not be excluded. This study investigated the potential correlations between the anti-inflammatory activity (AIA) and the phytocompound taste and/or its chemical class. The study relies on information gathered by an extensive literature (articles, books, databases) search and made public as PlantMolecularTasteDB. Out of a total of 1527 phytotastants with reliably documented taste and structure available in PlantMolecularTasteDB, 592 (for each of which at least 40 hits were found on PubMed searches) were included in the statistical analysis. A list of 1836 putative molecular targets of these phytotastants was afterwards generated with SwissTargetPrediction tool. These targets were systematically evaluated for their potential role in inflammation using an international databases search. The correlations between phytochemical taste and AIA, between chemical class and AIA, and between the taste and the number of inflammation related targets were statistically analyzed. Phytochemical taste may be a better predictor of AIA than the chemical class. Bitter phytocompounds have a higher probability of exerting AIA when compared with otherwise phytotastants. Moreover, bitter phytotastants act upon more inflammation related targets than non-bitter tasting compounds.
Open AccessPhytochemicals and Inflammation: Is Bitter Better?
The taste of a herb influences its use in traditional medicine. A molecular basis for the taste-based patterns ruling the distribution of herbal (ethno) pharmacological activities may not be excluded. This study investigated the potential correlations between the anti-inflammatory activity (AIA) and the phytocompound taste and/or its chemical class. The study relies on information gathered by an extensive literature (articles, books, databases) search and made public as PlantMolecularTasteDB. Out of a total of 1527 phytotastants with reliably documented taste and structure available in PlantMolecularTasteDB, 592 (for each of which at least 40 hits were found on PubMed searches) were included in the statistical analysis. A list of 1836 putative molecular targets of these phytotastants was afterwards generated with SwissTargetPrediction tool. These targets were systematically evaluated for their potential role in inflammation using an international databases search. The correlations between phytochemical taste and AIA, between chemical class and AIA, and between the taste and the number of inflammation related targets were statistically analyzed. Phytochemical taste may be a better predictor of AIA than the chemical class. Bitter phytocompounds have a higher probability of exerting AIA when compared with otherwise phytotastants. Moreover, bitter phytotastants act upon more inflammation related targets than non-bitter tasting compounds.
- Open Access
- 12 January 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 751712
PlantMolecularTasteDB: A Database of Taste Active Phytochemicals
PlantMolecularTasteDB: A Database of Taste Active Phytochemicals
- 12 January 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 751712
Open AccessPlantMolecularTasteDB: A Database of Taste Active Phytochemicals
PlantMolecularTasteDB: A Database of Taste Active Phytochemicals